Cancer drugs developed by Pfizer (PFE) and Novartis got priority review while Bristol-Myers is being considered the next acquisition target.
- Motley Fool•4 days ago
The drugmaker announced a delay to approval of its three-times-weekly version of Glatopa.
- Motley Fool•7 days ago
GlaxoSmithKline and Novartis are two high-yield dividend stocks that might be grossly undervalued.
NVS.BA : Summary for NOVARTIS AG CEDEAR EACH REP 0.5 - Yahoo Finance
NOVARTIS AG CEDEAR EACH REP 0.5 (NVS.BA)
Buenos Aires - Buenos Aires Delayed Price. Currency in ARS
Add to watchlist
|Day's Range||577.00 - 577.00|
|52 Week Range||566.85 - 585.00|
|PE Ratio (TTM)||N/A|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|